Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MARKIBD

Financiado

Cerrado

Alternative promoters as biomarkers in Inflammatory Bowel Disease

"Inflammatory Bowel Disease (IBD) affects up to 1 in 200 individuals in Europe. Current diagnosis of the two main subtypes of IBD (Crohn’s disease and ulcerative colitis) is based on endoscopy, radiology and the examination of bio... ver más

Fecha desconocida

UCPH

221K€

Presupuesto del proyecto: 221K€

Líder del proyecto

KOBENHAVNS UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto No tenemos la información de la convocatoria

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

UCPH

0.00€ | Lider

Proyectos interesantes

IBD-CHARACTER

Medical Technol...

Data Science

8M€ Cerrado

IBD-BIOM

Medical Technol...

Data Science

9M€ Cerrado

IPEIBD

Medical Technol...

Data Science

212K€ Cerrado

RTI2018-096946-B-I00

Medical Technol...

Data Science

242K€ Cerrado

TRANS_CEDAR

Medical Technol...

Data Science

170K€ Cerrado

REINFORCE

Medical Technol...

Data Science

536K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

KOBENHAVNS UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 221K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto "Inflammatory Bowel Disease (IBD) affects up to 1 in 200 individuals in Europe. Current diagnosis of the two main subtypes of IBD (Crohn’s disease and ulcerative colitis) is based on endoscopy, radiology and the examination of biopsies with a high degree of uncertainty: 20% of patients are not classifiable or are rediagnosed later. The uncertainty in diagnosis extends also to medication, which is to a large degree based on trial and error. The use of molecular biomarkers could allow for an earlier and more specific diagnosis of disease type and more targeted therapy; this is the aim of my project. My hypothesis is that differences between inflamed and non-inflamed tissue and between disease subtypes may not only be due to differential gene expression but also to alternative promoter usage, which may lead to altered protein products with modified or aberrant function. I will apply genome-wide experimental and computational methods to study differential promoter usage i) in colon tissue biopsies from IBD patients and ii) in the model system Caco-2, where we can investigate the effect of inflammation and perform functional validation of the promoters found in patients. The aim of this is to identify alternative promoters as biomarkers for diagnostics. As one of very few research groups worldwide, my host group uses a novel technique, Cap Analysis of Gene Expression, to identify transcription start sites genome-wide, which will allow me to quantify promoter usage and to find alternative promoters. Through the project I will obtain expertise in the growing field of high-throughput sequencing analysis, while my background in bioinformatics and immunology will contribute to the success of the project. As a result, the project will provide biomarkers for diagnosis of disease subtype with the aim to make diagnosis of IBD easier and more precise, allowing for better treatment and thereby improving the quality of life for patients as well as reducing health care costs."

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores